Danielle Brill Stock Analyst Profile - Raymond James Research Coverage - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Danielle Brill

    Stock Analyst at Raymond James

    (3.7)
    # 2430
    Out of 5,477 analysts
    98
    Total ratings
    Success rate
    Average return
    Main Sectors:
    Healthcare
    Top Industries:
    Biotechnology Drug Manufacturers - Specialty & Generic Drug Manufacturers - General
    30 Stocks
    Name Action PT Current % Upside Ratings Updated
    VRTX Vertex Pharmaceutica...
    Initiates Coverage On: Market Perform
    n/a
    		n/a n/a 3 Sep 3, 2025
    IRON Disc Medicine
    Initiates Coverage On: Buy
    86
    		59.94 43.48% 6 Jul 21, 2025
    ALNY Alnylam Pharmaceutic...
    Initiates Coverage On: Buy
    385
    		469.31 -17.96% 1 Jul 21, 2025
    HRMY Harmony Biosciences ...
    Initiates Coverage On: Buy
    48
    		33.21 44.53% 8 Jul 21, 2025
    PVLA Palvella Therapeutic...
    Initiates Coverage On: Buy
    56
    		59.73 -6.24% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    64
    		17.31 269.73% 2 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    163
    		141.25 15.4% 6 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    66
    		52.96 24.62% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    30
    		22.71 32.1% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Buy
    24
    		18.04 33.04% 1 Jul 21, 2025
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Upgrades: Strong Buy
    20 52
    		17.48 197.48% 6 Dec 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 1 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    79
    		54.5 44.95% 1 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    18
    		9.57 88.09% 1 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    36
    		16.2 122.22% 4 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    150
    		17.22 771.08% 3 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Strong Buy
    605
    		762.89 -20.7% 7 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Market Perform
    n/a
    		n/a n/a 5 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    50
    		37.11 34.73% 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Reinstates: Outperform
    51
    		35.68 42.94% 2 Oct 10, 2024
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Maintains: Outperform
    180 100
    		7.05 1318.44% 5 Nov 14, 2023
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Underperform
    n/a
    		n/a n/a 9 Sep 18, 2023
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Market Perform
    n/a
    		n/a n/a 5 Jun 27, 2023
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Market Perform
    n/a
    		n/a n/a 3 Oct 4, 2021
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Neutral
    75 50
    		n/a n/a 5 Jan 20, 2021
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Market Perform
    n/a
    		n/a n/a 1 Aug 25, 2020
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Initiates Coverage On: Market Perform
    n/a
    		n/a n/a 1 Aug 25, 2020
    XXXX
    XXXXXXXXXXXXXXXX
    Upgrade
    Downgrades: Hold
    n/a
    		n/a n/a 3 Sep 17, 2019